Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1C9RN | ISIN: US53220K5048 | Ticker-Symbol: LGDN
Tradegate
28.03.24
09:30 Uhr
66,00 Euro
0,00
0,00 %
1-Jahres-Chart
LIGAND PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LIGAND PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
67,5068,0021:30
66,5069,0021:00

Aktuelle News zur LIGAND PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLigand Pharmaceuticals gains amid bullish investor pitch1
29.02.LIGAND PHARMACEUTICALS INC - 10-K, Annual Report-
28.02.Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges1
28.02.Ligand Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary2
27.02.Why Is Ligand Pharmaceuticals Stock Trading Higher Today?3
27.02.Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M5
27.02.Ligand Pharmaceuticals Inc Q4 Earnings Summary232WASHINGTON (dpa-AFX) - Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):Earnings: $18.19 million in Q4 vs. -$17.49 million in the same period last year. EPS: $1.03 in...
► Artikel lesen
27.02.LIGAND PHARMACEUTICALS INC - 8-K, Current Report2
27.02.Ligand Reports Fourth Quarter and Full Year 2023 Financial Results463SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating...
► Artikel lesen
26.02.Ligand Pharmaceuticals' Earnings: A Preview2
22.02.Esai gets Japanese approval for epilepsy drug using Ligand technology1
08.01.Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel2
08.01.Ligand Pharma up after at-home viral skin infection treatment gets US approval2
08.01.FDA grants approval for Ligand's molluscum contagiosum treatment1
08.01.After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi3
05.01.Ligand Pharma up after US FDA nod for its topical skin drug2
05.01.Ligand Pharma's at-home skin treatment gets FDA approval3
05.01.FDA approves Ligand's Zelsuvmi for treatment of molluscum1
05.01.Ligand Pharma's topical skin drug gets US FDA approval1
05.01.Ligand Pharmaceuticals Incorporated: U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum132SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI (berdazimer topical gel, 10.3%)...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1